Analysis of hypoglycaemic effects of cannabidiol following oral and intraperitoneal administration in healthy rats

Elona Djemaili[1]; Elena Rafailovska[2]; Aleksandar Dimkovski[3]; Evgenija Mihajloska[3]; Zorica Naumovska[3]; Gjose Stefkov[3]; Biljana Miova[2]; Ljubica Suturkova[3]

[1]Department of Pharmacy, Faculty of Medical Sciences, University of Tetova, Ilinden bb, 1200 Tetovo, R.N. Macedonia
[2]Department of Physiology and Biochemistry, Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, Arhimedova 3, 1000 Skopje, R.N. Macedonia.
[3] Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Mother Tereza 47, 1000 Skopje, R.N. Macedonia

Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder with complex ethyology. It is characterized by a failure of glucose homeostasis and disturbances of carbohydrate, protein and lipid metabolism, attributed to defects in insulin secretion and/or insulin effect. Standard antidiabetic therapy comprises exogenous insulin and/or various oral antidiabetic medications, which are associated with serious adverse effects (Jadoon et al., 2016).

The most abundant non-psychotropic cannabinoid from *Cannabis sativa* is cannabidiol (CBD), which is known for its extensive spectrum of biological activities and favourable safety profile (Lim et al., 2021). Previously conducted studies disclosed that CBD administration is related to great therapeutic potential for treatment of streptozotocin (STZ)-induced DM, mostly affecting the oxidative stress, inflammation, and cell death (Jadoon et al., 2016). However, there are some discrepancies in the literature concerning whether or not CBD has a direct effect on blood glucose levels, both, in animal models (Frisher et al., 2010) and in humans (Jadoon et al., 2016; Mattes et al., 2021). These inconsistencies are likely due to the different doses and administration routes of CBD used in distinctive studies.

OBJECTIVE *To investigate the potential hypoglycaemic effects of different doses of CBD in healthy rats. To compare the effectiveness of the same doses of CBD given both orally and via intraperitoneal route of administration in rats.*

Further investigations will be made in diabetic rats, for estimation of the potential antihyperglycemic effects of CBD oil.

Materials and methods

CBD oil preparation

CBD extract was obtained by CO_2 extraction of Cannabis flos (decarboxylated), diluted with olive oil to 25% (w/w).

Animals and treatment

Oral glucose tolerance test (OGTT)

After an overnight fast (8h), basal glycaemia was measured from the tail vein using a glucose oxidase-peroxidase reactive strips (and a glucometer (Plusmed, Istanbul, Turkey). Water as a control, metformin or CBD oil in previously defined doses and administration routes were given to each animal according to which group it was randomized. Thirty minutes later, animals received glucose solution (2 g/kg), using a gavage. Blood samples were collected immediately after glucose administration and then after 15, 30, 45, 60, 90 and 120 min. respectively, in order to obtain the glycaemic area under the curve (AUC).

Statistical analysis

Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Tukey's *post hoc* test. The results were considered statistically significant at $p \leq 0.05$. GraphPad Prism (ver. 9) software was used for statistical analysis.

Results and discussion

The results obtained from the OGTT showed that all three groups that were given CBD intraperitoneally, as well as the metformin-receiving group, have overall similar dynamics towards blood glucose levels during the 120 minute time period. However, there was no significant difference in the overall response between the different doses of CBD regarding the AUC (Figure 1).

In the OGTT measurements in the CBD-receiving groups via oral route, glucose levels in all three groups peaked at similar levels 15 minutes after the glucose administration. The group treated with 50 mg/kg CBD showed a significantly lower increase in glucose levels over the first 15 min after glucose administration, compared to the control and metformin-treated groups. The CBD-treated groups with doses of 0.5 mg/kg and 50 mg/kg reached the values obtained in the control group 60 minutes after glucose administration, while the rats treated with 5 mg/kg CBD reached control values after 90 minutes. The glycemic AUC value for the treatment with 50 mg/kg CBD was approximately 10% lower than the AUC value for the metformin-treated group ($p \leq 0.05$). In addition, when compared with the rats treated with 0.5 mg/kg and 5 mg/kg CBD, the AUC values were lower by 10% and 15% lower respectively. Moreover, orally given CBD at the dose of 50 mg/kg had the best overall glucose response (Figure 2).


Figure 1.
Oral glucose tolerance test (OGTT) and area under the curve (AUC) after intraperitoneal administration of CBD.
C-control group; Met-metformin-receiving group; CBD1-CBD(0.5 mg/kg) receiving group; CBD2-CBD(5 mg/kg)-receiving group; CBD3-CBD(50 mg/kg)-receiving group;

Figure 2.
Oral glucose tolerance test (OGTT) and area under the curve (AUC) after oral administration of CBD.
C-control group; Met-metformin-receiving group; CBD1-CBD(0.5 mg/kg) receiving group; CBD2-CBD(5 mg/kg)-receiving group; CBD3-CBD(50 mg/kg)-receiving group;

Conclusion Oral and intraperitoneal application of CBD generates hypoglycaemic effects in healthy rats subjected to OGTT. Moreover, the dose of 50 mg/kg, administered via oral route, was more effective than the standard hypoglycaemic agent metformin. These findings raise the possibility that potential mechanisms underlying these effects could have novel application in therapeutics for diabetes.

REFERENCES

Frisher, M., White, S., Varbiro, G., Voisey, C., Perumal, D., Crome, I., Khideja, N. and Bashford, J., 2010. The role of cannabis and cannabinoids in diabetes. Br. J. Diabetes Vasc. Dis., 10(6), pp.267-273.

Jadoon, K.A., Ratcliffe, S.H., Barrett D.A., Thomas E.L., Stott C., Bell J.D., O'Sullivan S.E., Tan G.D., 2016. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo- Controlled, Parallel Group Pilot Study. Diabetes Care, 39(10), pp.1777–1786.

Lim, X.Y., Tan, T.Y.C., Muhd Rosli, S.H., Sa'at, M.N.F., Sirdar Ali, S. and Syed Mohamed, A.F., 2021. Cannabis sativa subsp. sativa's pharmacological properties and health effects: A scoping review of current evidence. PloS One, 16(1).

Mattes, R.G., Espinosa, M.L., Oh, S.S., Anatrella, E.M. and Urteaga, E.M., 2021. Cannabidiol (CBD) Use in Type 2 Diabetes: A Case Report. Diabetes Spectr., 34(2), pp.198- 201.